Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Free Webinar - Master Forex Trading Today! Don't Miss Out | Tuesday, June 6, 2023 | 01:00PM EDT Enroll Now
Close

Mithra Pharmaceuticals Sa (MITRA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
2.31 +0.01    +0.43%
05/06 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Belgium
ISIN:  BE0974283153 
  • Volume: 69,443
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 2.31 - 2.37
Mithra Pharmaceuticals Sa 2.31 +0.01 +0.43%

MITRA Income Statement

 
Featured here, the Income Statement (earnings report) for Mithra Pharmaceuticals Sa, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Collapse All
Period Ending: 2022
31/12
 2022
30/09
 2022
30/06
 2022
31/03
Total Revenue 27.82 27.82 5.68 5.68
Revenue 27.82 27.82 5.68 5.68
Other Revenue, Total - - - -
Cost of Revenue, Total 6.27 6.27 3.54 3.54
Gross Profit 21.55 21.55 2.14 2.14
Total Operating Expenses 27.17 27.17 19.45 19.45
Selling/General/Admin. Expenses, Total 4.27 4.27 4.11 4.11
Research & Development 18.26 18.26 13.76 13.76
Depreciation / Amortization -2.91 -2.91 2.91 2.91
Interest Expense (Income) - Net Operating -4.68 -4.68 -3.82 -3.82
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 5.96 5.96 -1.06 -1.06
Operating Income 0.646 0.646 -13.77 -13.77
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - - -
Other, Net -8.09 -8.09 0.707 0.707
Net Income Before Taxes 8.74 8.74 -14.48 -14.48
Provision for Income Taxes 22.92 22.92 1.15 1.15
Net Income After Taxes -14.19 -14.19 -15.62 -15.62
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items -14.19 -14.19 -15.62 -15.62
Total Extraordinary Items - - - -
Net Income -14.19 -14.19 -15.62 -15.62
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items -14.19 -14.19 -15.62 -15.62
Dilution Adjustment 0.2 0.2 -0.084 -0.084
Diluted Net Income -14.39 -14.39 -15.54 -15.54
Diluted Weighted Average Shares 53.08 53.08 45.04 45.04
Diluted EPS Excluding Extraordinary Items -0.271 -0.271 -0.347 -0.347
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS -0.053 -0.053 -0.231 -0.231
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

MITRA Comments

Write your thoughts about Mithra Pharmaceuticals Sa
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Grégory Vervoort
Grégory Vervoort Aug 12, 2022 4:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mega deal to come with catalent (CTLT) ?
Reply
0 0
Report
Filip dB
Phildb Aug 10, 2022 3:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) *******hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
Reply
0 0
Report
Filip dB
Phildb Aug 01, 2022 3:15AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
Reply
2 0
Report
Filip dB
Phildb Jul 26, 2022 2:20AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
NEXSTELLIS® oral contraceptive now available in Australia26 July 2022, 07:30 CEST Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXSTELLIS ® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia. NEXTSTELLIS® unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman’s body responds differently to contraceptive hormones and having a new estrogen available – E4 – opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS® contraceptive on a third continent. Leon Van Rompay, CEO Mithra Women’s Health
Reply
0 0
Report
Filip dB
Phildb Jul 01, 2022 7:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement, leaving EUR 54 million available to Mithra.
Reply
0 0
Report
Golden Age
Global_K May 06, 2022 5:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1 month later and 8.16, where's the bottom?
Reply
0 0
Report
Golden Age
Global_K Apr 06, 2022 6:09AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
11.70, curious how low this can go. price now certainly does not represent future profits
Reply
0 0
Report
Golden Age
Global_K Mar 08, 2022 3:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
14.00? Time to accumulate for a near future
Reply
0 0
Report
Sonic the hedgehog
Sonic the hedgehog Mar 26, 2021 9:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Approval in EU is a fact. next US!
Reply
3 0
Report
Robert Jacketti
Robert Jacketti Mar 26, 2021 9:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Approval US is also a fact !
Reply
1 0
Report
Jozef De Neuter
Jozef De Neuter Mar 15, 2021 3:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Approval for Canada is now a fact!
Reply
2 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email